Marché indien des médicaments contre la pneumonie contractée dans la communauté – Tendances et prévisions de l’industrie jusqu’en 2031

Analyse et perspectives du marché indien des médicaments contre la pneumonie acquise dans la communauté

L’un des principaux facteurs de croissance du marché est la prévalence croissante de la pneumonie. En outre, la sensibilisation croissante et l’augmentation des dépenses de santé constituent un autre facteur clé de la croissance du marché. Cependant, l’accessibilité et la sensibilité au prix des médicaments freinent la croissance du marché. Les solutions technologiques et l’innovation devraient constituer une opportunité de croissance du marché. Cependant, l’infrastructure et l’accès limités aux soins de santé peuvent constituer un défi à la croissance du marché.

Data Bridge Market Research analyse que le marché indien des médicaments contre la pneumonie acquis par la communauté devrait atteindre 163,52 millions USD d'ici 2031, contre 92,72 millions USD en 2023, avec un TCAC de 7,5 % au cours de la période de prévision de 2024 à 2031.

Définition du marché

La pneumonie communautaire (PC) désigne un type de pneumonie contractée en dehors des hôpitaux ou des établissements de santé. Il s’agit d’une maladie infectieuse courante caractérisée par une inflammation du tissu pulmonaire due à une infection par des bactéries, des virus, des champignons ou d’autres agents pathogènes. La PC touche des personnes de tous âges, mais elle est particulièrement répandue chez les enfants, les personnes âgées et les personnes souffrant de problèmes de santé sous-jacents ou d’un système immunitaire affaibli.

Dynamique du marché indien des médicaments contre la pneumonie contractée dans la communauté

This section deals with understanding the market drivers, opportunities, restraints, and challenges. All of this is discussed in detail below:     

Driver

• Rising Prevalence of Pneumonia

The rising prevalence and burden of pneumonia in India present a substantial opportunity for the Community-Acquired Pneumonia (CAP) drug market in the country. With pneumonia being a leading cause of morbidity and mortality, particularly among vulnerable populations such as children and the elderly, there is an increasing demand for effective and accessible treatments. This heightened need creates a market opportunity for pharmaceutical companies to innovate, develop, and provide a diverse range of pneumonia drugs tailored to address the evolving strains and challenges associated with the disease.

• Growing Antibiotic Resistance Pathogen Causing Pneumonia

The growing rate of antibiotic-resistant pathogens causing pneumonia presents a unique feature for the Community-Acquired Pneumonia (CAP) drug market in India. There is an urgent need for innovative and effective treatments to combat evolving microbial threats, as antibiotic resistance becomes a global concern. India, with its thriving pharmaceutical industry, has the potential to lead in the development of new antibiotics and alternative therapies. Indian pharmaceutical companies can contribute valuable solutions to the global healthcare landscape by investing in research and development to address antibiotic-resistant strains. In addition, initiatives that prioritize research on antibiotic stewardship and combination therapies can further enhance India standing in addressing the complex issue of antibiotic resistance in pneumonia treatment.

Opportunity

• Technology-Driven Solutions and Innovation

Leveraging advanced technologies, such as artificial intelligence, data analytics, and telemedicine, can streamline various aspects of the healthcare system. This includes improved diagnostic capabilities, personalized treatment plans, and efficient supply chain management for pneumonia drugs. In addition, innovative approaches in drug development, such as novel formulations or drug delivery systems, can enhance the efficacy and patient adherence to treatments. The adoption of digital platforms for healthcare services, including remote patient monitoring and virtual consultations, can overcome geographical barriers, ensuring that even rural populations have access to timely medical interventions. Embracing technology not only enhances the overall efficiency of healthcare delivery but also positions India as a leader in healthcare innovation, contributing to the advancement of the CAP drug market both domestically and on the global stage. This convergence of technology and healthcare presents an opportunity for India to create a more resilient, accessible, and patient-centric market.

Restraints/Challenges

• Affordability and Price Sensitivity Associated with the Drugs

With a diverse socioeconomic landscape and a large population facing varying levels of financial constraints, the cost of medications becomes a critical factor in healthcare access. Pneumonia, as a prevalent respiratory infection, necessitates timely and effective treatment, but the financial burden associated with pharmaceuticals can hinder patients from seeking necessary medications promptly. Price sensitivity among the population, coupled with the high prevalence of CAP, poses challenges for pharmaceutical companies to strike a balance between offering quality drugs and ensuring they are economically viable for a broad segment of the population. The affordability constraint may lead to delayed or inadequate treatment, impacting health outcomes and potentially contributing to the persistence of pneumonia-related morbidity and mortality in India.

• Limited Healthcare Infrastructure and Access

The lack of accessible healthcare services makes it difficult for individuals to receive timely and quality medical care, including diagnosis and treatment for various health conditions.

This limitation in infrastructure and access can lead to delayed medical interventions, exacerbation of health issues, and a higher burden of preventable diseases. Individuals may face challenges in reaching healthcare facilities promptly, obtaining necessary diagnostic tests, and accessing appropriate pneumonia drugs.

Recent Developments

• In September 2023, Astrazeneca has received an approval from the Central Drugs Standard Control Organisation (CDSCO) to import and market a medication to prevent Respiratory Syncytial virus. This will help the company to strengthen its presence in India market
• In May 2021, Teva Pharmaceutical Industries Ltd. announced the launch of its 250 mg and 500 mg strength generic Erythromycin tablets—a therapeutic equivalent for the Reference Listed Drug (RLD) Erythromycin Tablets from Arbor Pharmaceuticals. This has helped the company to strengthen its product portfolio

India Community Acquired Pneumonia Drugs Market Scope

The India community acquired pneumonia drugs market is segmented into nine notable segments based on product, route of administration, dosage, product type, mode of purchase, type, population type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the differences in your target markets.

Product

• Macrolides
• B-Lactam Antibiotics
• Quinolones
• Tetracycline
• Carbapenem
• Glycopeptide Antibiotics
• Pleuromutilin
• Others

On the basis of product, the market is segmented into macrolides, B-lactam antibiotics, quinolones, tetracycline, carbapenem, glycopeptide antibiotics, pleuromutilin, and others.

Route of Administration

• Oral
• Intravenous

On the basis of route of administration, the market is segmented into oral and intravenous.

Dosage

• Tablet
• Solution

On the basis of dosage, the market is segmented into tablet and solution.

Product Type

• Génériques
•  De marque

En fonction du type de produit, le marché est segmenté en produits génériques et produits de marque.

Mode d'achat

• Ordonnance
•  En vente libre

Sur la base du mode d’achat, le marché est segmenté en médicaments sur ordonnance et en vente libre.

Taper

• Bactérien
• Virus
• Champignons

Sur la base du type, le marché est segmenté en bactéries, virus et champignons.

Type de population

• Enfants
•  Gériatrie
•  Adultes

En fonction du type de population, le marché est segmenté en enfants, gériatrie et adultes.

Utilisateur final

• Hôpitaux
•  Cliniques spécialisées
•  Soins à domicile
•  Autres

Sur la base de l’utilisateur final, le marché est segmenté en hôpitaux, cliniques spécialisées, soins à domicile et autres.

Canal de distribution

• Pharmacie de l'hôpital
•  Pharmacie de détail
•  Pharmacie en ligne
•  Autres

Sur la base du canal de distribution, le marché est segmenté en pharmacie hospitalière, pharmacie de détail, pharmacie en ligne et autres.

Analyse de la concurrence et des parts de marché des médicaments contre la pneumonie acquise en Inde

Le paysage concurrentiel du marché des médicaments contre la pneumonie acquis par la communauté indienne fournit des détails sur les concurrents. Les détails inclus sont la présentation de l'entreprise, les finances de l'entreprise, les revenus générés, le potentiel du marché, les investissements en R&D, les nouvelles initiatives du marché, les sites et installations de production, les forces et les faiblesses de l'entreprise, le lancement du produit, les approbations de produits, la largeur et l'étendue du produit, la domination des applications et la courbe de survie du type de produit. Les points de données ci-dessus fournis ne concernent que l'orientation de l'entreprise sur le marché.

Certains des principaux acteurs du marché opérant sur le marché sont Pfizer Inc., Cipla Inc., AstraZeneca, Abbott, Teva Pharmaceutical Industries Ltd., Novartis AG, Fresenius Kabi, Baxter et Aurobindo Pharma USA, entre autres. 

SKU-70632